Shanghai, China, and Heidelberg, Germany – October 16, 2024 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated global radiotherapeutics company, today announced that the Company will be presenting at the 37th Annual Congress of the European Association of Nuclear Medicine ("EANM"), which will be held in Hamburg, Germany, from October 19-23, 2024. Juan Zhang, Ph.D, Senior Vice President and Head of Biology, and Taishan Hu, Ph.D, Senior Vice President and Head of Medicinal Chemistry, will give three preclinical presentations which have been accepted as Top Rated Oral Presentation ("TROP").

Heidelberg, Germany, Gembloux, Belgium, and Shanghai, China — September 3, 2024 — Full-Life Technologies, a fully integrated global radiotherapeutics company, today announced attendance of the Morgan Stanley 22nd Annual Global Healthcare Conference in New York.

Heidelberg, Germany and Seoul, Korea, July 17, 2024 – Full-Life Technologies (“Full-Life”), a fully integrated global radiotherapeutics company, announced today that it has entered into a license agreement with SK Biopharmaceuticals, a global biotech company, for exclusive worldwide clinical research, development, manufacturing, and commercialization rights to Full-Life's "FL-091" radiopharmaceutical compound targeting neurotensin receptor 1 (NTSR1) positive cancers.

Heidelberg, Germany – July 3, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ²²⁵Ac-FL-020.

Shanghai, China, and Heidelberg, Germany – June 11, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, released preclinical data of its NTSR1-targeting RDC program FL-091 in an oral presentation at the 2024 SNMMI Annual Meeting.